Terns Pharmaceuticals Inc (TERN)

Merck Completes Acquisition of Terns Pharmaceuticals, Inc.May 5, 2026 8:45 AM
Business Wire Addition of TERN-701, a novel investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor, further diversifies Merck’s oncology pipeline Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the successful completion of the acquisition of Terns Pharmaceuticals, Inc. (“Terns”) (Nasdaq: TERN). “The Terns acquisition reflects Merck’s continued focus on science-driven, value-enhancing business development aimed at bringing meaningful innovation to patients,” said Robert M. Davis, chairman and chief executive officer, Merck. “We believe TERN-701 has the potential to become a differentiated treatment option for certain patients with chronic myeloid leukemia, and we look forward to working with the Terns team to advance its clinical development.” TERN-701 was recently granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia (CML) in the chronic phase without the T315I mutation previously treated with two or more tyrosine kinase inhibitors (TKIs). The BTD designation for TERN-701 is based on data from the ongoing Phase 1/2 CARDINAL trial (NCT06163430). Transaction details Merck completed the cash tender offer, through a subsidiary, for all the outstanding shares of common stock of Terns at a purchase price of $53.00 per share, without interest and subject to any applicable tax withholding. As of the tender offer expiration at one minute after 11:59 p.m., Eastern Time, on May 4, 2026, 100,091,794 shares of Terns common stock were validly tendered and not validly withdrawn, representing approximately 86.36% of the total number of Terns’ issued and outstanding shares of common stock as of such date and time. All such shares have been accepted for payment in accordance with the terms of the tender offer, and Merck, on behalf of its subsidiary, will promptly pay for such shares. Following the completion of the tender offer, Merck completed the acquisition of Terns through a merger of Merck’s wholly-owned subsidiary with and into Terns, with Terns being the surviving corporation, in which all shares of Terns common stock issued and outstanding at the effective time of the merger were converted into the right to receive cash equal to the $53.00 offer price per share, without interest and subject to any applicable tax withholding. At the completion of the merger, Terns became a wholly-owned subsidiary of Merck and Terns’ common stock will no longer be listed or traded on the Nasdaq Global Select Market. The transaction is expected to be accounted for as an asset acquisition, resulting in a charge to research and development expense of approximately $5.8 billion, or approximately $2.35 per share, included in both second quarter and full year 2026 GAAP and non-GAAP results. Additionally, GAAP and non-GAAP EPS are expected to be negatively impacted by approximately $0.12 per share in 2026, representing costs associated with advancing TERN-701 and costs of financing. About TERN-701 TERN-701 is a novel investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor (TKI) designed to bind to the ABL myristoyl pocket, with a potentially best-in-disease profile that could improve upon existing treatments for certain patients with chronic myeloid leukemia (CML). About chronic myeloid leukemia Chronic myeloid leukemia (CML) is a slow growing type of blood cancer that leads to an overproduction of white blood cells that accumulate in the blood and bone marrow, disrupting the production of healthy blood cells. CML is commonly associated with the Philadelphia chromosome, a translocation between chromosomes 9 and 22 that results in constitutive activation of the BCR::ABL1 fusion protein, which fuels cancer growth. About Merck in hematology Merck is advancing a pipeline of hematology candidates targeting a diverse range of targets across leukemias, lymphomas and myeloproliferative neoplasms. Candidates in Phase 3 development include: bomedemstat (MK-3543), an investigational, orally available lysine-specific demethylase 1 (LSD1) inhibitor; nemtabrutinib (MK-1026), an investigational, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor; and zilovertamab vedotin (MK-2140), an investigational antibody-drug conjugate (ADC) that targets receptor tyrosine kinase-like orphan receptor 1 (ROR1). Additionally, MK-1045, an investigational CD19xCD3 T-cell engager, is currently being evaluated in a Phase 1b/2 trial. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “anticipates,” “expects,” “intends,” “believes,” “may,” “plan” or “will.” There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, such as general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by law. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2025, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and the company’s other filings with the SEC available at the SEC’s Internet site (www.sec.gov). View source version on businesswire.com: https://www.businesswire.com/news/home/20260505216715/en/ Media Contacts: Carly Myar
carly.myar@merck.com Michael Levey
michael.levey@merck.com Investor Contacts: Peter Dannenbaum
(732) 594-1579 Steven Graziano
(732) 594-1583 Original: Merck Completes Acquisition of Terns Pharmaceuticals, Inc.

Terns Pharma stock jumps on report of potential $6B takeover by MerckMarch 25, 2026 6:52 AM
IH Market News
Terns Pharmaceuticals (NASDAQ:TERN) shares surged in premarket trading after a report indicated that Merck & Company (NYSE:MRK) is close to agreeing a deal to acquire the biotech firm for roughly $6 billion.According to the Financial Times, the proposed all-cash transaction could be finalized within days and would value Terns at a premium to its current market capitalization of around $5.3 billion, citing people familiar with the matter.Terns shares rose about 14% in premarket trading by 05:15 ET following the report.The potential acquisition would represent another step by Merck to strengthen its drug pipeline ahead of the looming patent expiry of its blockbuster cancer treatment Keytruda, which generates roughly $30 billion in annual revenue and may lose exclusivity as early as 2028.“If confirmed, potential Terns acquisition by Merck would be one of the best deals the company has made since its spree began ahead of the Keytruda LOE (loss of exclusivity),” said Evan David Seigerman, an analyst at BMO Capital Markets, in a note.“Terns would be a natural fold in to Merck’s existing oncology portfolio, likely allowing the company to provide its expertise in oncology trial design and execution to make the most of TERN-701 in chronic myeloid leukemia (CML) while providing a potential multi-billion dollar revenue opportunity to Merck, in the back half of the decade,” he added.Merck has stepped up its acquisition activity in recent months as it looks to offset future revenue pressure. Last year the company acquired Verona Pharma for $10 billion and Cidara Therapeutics for $9.2 billion.Terns’ lead development candidate targets chronic myeloid leukemia (CML), a rare form of blood and bone marrow cancer. The therapy could eventually compete with Scemblix, a treatment marketed by Novartis.Merck stock priceTerns Pharmaceuticals stock price

Original: Terns Pharma stock jumps on report of potential $6B takeover by Merck

$TERN: No stopping it now.......... $16

How much higher does it really wanna go ???????????

$50 ???

Mannnnnnnnnnnnnnnnnnnnnnnnnnnnnn


GO $TERN

$TERN: BOooommmmmmmmmm............ now $13

Just like that yo............ Monday Morning.

From $8.20 just 20mins ago.


BOom boom week ahead


GO $TERN